452 related articles for article (PubMed ID: 34936125)
1. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
Zhulai G; Oleinik E
Scand J Immunol; 2022 Mar; 95(3):e13129. PubMed ID: 34936125
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
Liu M; Sun Q; Wei F; Ren X
Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
6. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
8. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
9. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
Kalantari Khandani N; Ghahremanloo A; Hashemy SI
J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
[TBL] [Abstract][Full Text] [Related]
11. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.
Córdova-Bahena L; Velasco-Velázquez MA
Rev Invest Clin; 2020 Oct; 73(1):008-016. PubMed ID: 33079077
[TBL] [Abstract][Full Text] [Related]
13. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
14. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
16. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
Luo M; Fu L
Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
[TBL] [Abstract][Full Text] [Related]
17. PD-L1-specific T cells.
Ahmad SM; Borch TH; Hansen M; Andersen MH
Cancer Immunol Immunother; 2016 Jul; 65(7):797-804. PubMed ID: 26724936
[TBL] [Abstract][Full Text] [Related]
18. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
19. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
20. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
